-+ 0.00%
-+ 0.00%
-+ 0.00%

Solid Biosciences wins EU orphan drug designation for Duchenne therapy SGT-003

PUBT·04/28/2026 12:11:18
Listen to the news
Solid Biosciences wins EU orphan drug designation for Duchenne therapy SGT-003
  • Solid Biosciences received European Commission orphan drug designation for SGT-003 to treat Duchenne muscular dystrophy.
  • Designation adds to regulatory momentum for SGT-003 as Solid advances global development.
  • Program remains in clinical testing, including INSPIRE DUCHENNE Phase 1/2 study and IMPACT DUCHENNE Phase 3 trial.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Solid Biosciences Inc. published the original content used to generate this news brief on April 28, 2026, and is solely responsible for the information contained therein.